What is the CA 15.3 Test?

The cancer antigen, 15.3, is a biological tumour marker that predicts the progression of breast cancer and response to treatment, and indicates the chances of recurrence. CA 15.3 is a biological molecule that is normally secreted by breast cells. However, in breast cancer patients, a higher amount is secreted by the malignant cells and this can enter the bloodstream. The molecule is secreted less in a localised breast tumour, but in the advanced stages of the disease, the test is highly useful for checking the prognosis.

    Enquire Now

    • Yes Same as WhatsApp number

    • By clicking on Send, you accept to receive communication from Yashoda Hospitals on email, SMS, call and Whatsapp.

    Need Any Medical Help?

    Talk to Our Health Care Experts!

    doctor avatar

    Need Any Medical Help?

    Have any Questions?

    Why Choose Yashoda Hospitals

    Yashoda Hospitals is committed to providing world-class treatment for patients from across the globe. With the unique combination of state-of-the-art technology, intuitive care, and clinical excellence, we are the healthcare destination for thousands of international patients in India.

    blank
    Comprehensive Care

    On the journey to good health, we understand that it is important for you to feel at home. We plan out all aspects of your trip.

    blank
    Expert Doctors

    Experienced specialists perform non-invasive and minimally invasive surgeries to provide the best treatment for international patients.

    blank
    Cutting-Edge Technology

    Our hospitals are equipped with advanced technology to perform a wide range of procedures and treatments.

    blank
    Clinical Excellence

    We deliver excellence by delivering quick and efficient healthcare and through pioneering research that helps all our future.patients.

    References

      1) Coppola, L., Cianflone, A., Pane, K. et al. The impact of different preanalytical methods related to CA 15.3 determination in frozen human blood samples: a systematic review. Syst Rev 10, 102 (2021).

      2)Al-azawi, D., Kelly, G., Myers, E. et al. CA 15.3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 6, 220 (2006).

    Frequently Asked Questions

    A sample of blood is collected by your healthcare provider and it is analysed using various assay kits like enzyme-linked immunoassay, chemiluminescence, and radioimmunoassay in the laboratory for detecting the antigen. The fresh blood sample is used for treatment purposes and for biomedical research; frozen human blood samples are used.

    The reference range of this antigen should be less than 25KU/l in 95%  of normal individuals and 88% of benign cancer cases,  but its upper limit will vary according to the amount shed by the malignant tumour cells.

    The test is used to detect advanced breast cancer lesions with chances of metastasis and recurrence. It also helps to know how well the patient is responding to the treatment 

     A sample of blood will be drawn by your healthcare laboratory and will be analysed in a medical laboratory. It is advisable to do the test in the same laboratory every time during follow-up as different laboratories follow different techniques and standards.

    The CA 15.3 level in a normal individual should be below 25 KU/l.

    No, this test cannot be used for screening breast cancer as it is also secreted by normal breast cells and lacks sensitivity and specificity for screening procedures.

    CA 15.3 also seems to be elevated in conditions like liver, lung or ovarian diseases. 

    Yes, CA 27-29 is a breast cancer tumour marker similar to CA 15.3.

    Follow the instructions given by your healthcare provider. Avoid drugs like biotin and afinitor as they can interfere with the test results. 

    The CA 15.3 test is highly specific in advanced stages of  breast cancer. However, the upper reference range of the molecule varies based on the tumour. 

    No, the test does not pose any significant risk as such, other than the rare chances of infection and bleeding from the site of blood collection.

    Doctors suggest evaluation of oestrogen and progesterone receptors and HER2  and gene expression to analyse the patient’s breast cancer.

    For further information, book an appointment and get a free second opinion at Yashoda hospitals